Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2001
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Riluzole oral film for treating amyotrophic lateral sclerosis TS ID 11779Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Edaravone for treating amyotrophic lateral sclerosis TS ID 11869Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC